Focus: Aura Biosciences is a Boston-based biotech company focused on delivering therapeutics via pseudo-viral vectors, with a concentrated pipeline in oncology and nephrology, particularly eye cancers. The company is pre-revenue and privately funded, operating at clinical stage with Phase 1-3 programs.
Profile data last refreshed 5h ago · AI intelligence enriched 2mo ago
Stable — net +3 jobs in 30d
5 added, 2 removed. Backfill posture.
Best fit for scientists or clinicians willing to embrace early-stage risk in exchange for deep technical ownership of a novel modality; not ideal for those seeking stability or broad organizational scope.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Aura Biosciences
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Aura Biosciences's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
+2 more
Fierce Biotech Layoff Tracker 2026: Sionna halves staff; Merck trims more NJ jobs - Fierce Biotech
Fierce Biotech Layoff Tracker 2026: Sionna halves staff; Merck trims more NJ jobs Fierce Biotech
Layoff Tracker: Merck adds 53 jobs to New Jersey chopping block - BioSpace
Layoff Tracker: Merck adds 53 jobs to New Jersey chopping block BioSpace
8-K Filing: LeonaBio, Inc. (LONA) (CIK 0001620463) — EX-99.1
EX-99.1
Aura lays off 20% of workforce, rejigs C-suite amid R&D refocus on eye cancer - Fierce Biotech
Aura lays off 20% of workforce, rejigs C-suite amid R&D refocus on eye cancer Fierce Biotech
8-K Filing: Obsidian Therapeutics, Inc. (OBX) (CIK 0002130606) — 8-K
8-K
8-K Filing: Bicara Therapeutics Inc. (BCAX) (CIK 0002023658) — EX-99.1
EX-99.1
Showing 6 of 10 news items
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
Meeting Report From the 2025 Cure Ocular Melanoma (CURE OM) Global Science Meeting, Amsterdam, the Netherlands, October 2025.
Early Efficacy and Exploratory Biomarker Data of Bel-sar in Patients with Intermediate-risk and High-risk Non-muscle-invasive Bladder Cancer.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo